We took into consideration different rare mutations observed in BRAF, PIK3CA, HER2, and NRAS detected with a total frequency equal to 16.7% of patients with lung adenocarcinoma harboring somatic mutations, which is not a negligible prevalence if transposed to the entire population. Here, ERBB2 is linked to lung adenocarcinoma.